JAGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Jaguar Health, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$2.82−0.71 (-20.00%)
Close on Oct 19, 2026
- Market cap
- $2.28M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Jaguar Health's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Iliad Management, LLC | 440,000 | 9.80% | 13G (passive) | Dec 11, 2025 |
| Joshua Mailman | 189,617 | 9.99% | 13G (passive) amendment | Sep 12, 2026 |
| John Fife and Fredrick Waid | 1,290,000 | 9.90% | 13G (passive) | Jan 29, 2025 |
| Heights Capital Management, Inc. | 103,912 | 9.90% | 13G (passive) | May 20, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lisa A. Conte | See Remarks, Director | 29,258 | 0.57% | Jan 21, 2026 |
| Jonathan S. Wolin | See Remarks | 11,938 | 0.23% | Jan 21, 2026 |
| Steven R. King | See Remarks | 11,885 | 0.23% | Jan 21, 2026 |
| Carol R. Lizak | Chief Financial Officer | 11,912 | 0.23% | Dec 15, 2025 |
| Pravin R. Chaturvedi | Chief Scientific Officer | 11,938 | 0.23% | Dec 15, 2025 |
| John Micek | Director | 7,430 | 0.14% | Mar 12, 2026 |
| Anula Jayasuriya | Director | 5,916 | 0.11% | Dec 15, 2025 |
| James J. Bochnowski | Director | 188,033 | 3.64% | Dec 15, 2025 |
| Jonathan B. Siegel | Director | 7,482 | 0.14% | Dec 15, 2025 |
| Alternative Strategies LLC Lincoln | 10% owner | 600,000 | 11.61% | Aug 29, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John Micek Director | Dec 11, 2025 | Award | +7,377 | – | – | 7,430 |
| Steven R. King See Remarks | Dec 11, 2025 | Award | +11,740 | – | – | 11,885 |
| Jonathan S. Wolin See Remarks | Dec 11, 2025 | Award | +11,740 | – | – | 11,938 |
| Lisa A. Conte See Remarks, Director | Dec 11, 2025 | Award | +28,592 | – | – | 29,258 |
| Carol R. Lizak Chief Financial Officer | Dec 11, 2025 | Award | +11,740 | – | – | 11,911 |
| Jonathan B. Siegel Director | Dec 11, 2025 | Award | +7,377 | – | – | 7,423 |
| James J. Bochnowski Director | Dec 11, 2025 | Award | +6,363 | – | – | 6,415 |
| Anula Jayasuriya Director | Dec 11, 2025 | Award | +5,870 | – | – | 5,916 |
| Pravin R. Chaturvedi Chief Scientific Officer | Dec 11, 2025 | Award | +11,740 | – | – | 11,938 |
| Lisa A. Conte CEO and President, Director | May 17, 2025 | Option exercise | +2 | – | – | 666 |
| Steven R. King See Remarks | May 17, 2025 | Option exercise | +1 | – | – | 145 |
| Steven R. King See Remarks | Oct 8, 2024 | Award | +4,922 | – | – | 4,951 |
| Jonathan S. Wolin See Remarks | Oct 8, 2024 | Award | +4,922 | – | – | 4,955 |
| Lisa A. Conte See Remarks, Director | Oct 8, 2024 | Award | +16,503 | – | – | 16,624 |
| Pravin R. Chaturvedi Chief Scientific Officer | Oct 8, 2024 | Award | +4,922 | – | – | 4,957 |
| Carol R. Lizak Chief Financial Officer | Oct 8, 2024 | Award | +4,280 | – | – | 4,297 |
| Lisa A. Conte CEO and President, Director | May 17, 2024 | Option exercise | +2,695 | – | – | 7,295 |
| Carol R. Lizak Chief Financial Officer | May 17, 2024 | Option exercise | +431 | – | – | 1,042 |
| Pravin R. Chaturvedi Chief Scientific Officer | May 17, 2024 | Option exercise | +871 | – | – | 2,141 |
| Jonathan S. Wolin Chief of Staff, CCO & GC | May 17, 2024 | Option exercise | +871 | – | – | 2,012 |
| Steven R. King See Remarks | May 17, 2024 | Option exercise | +612 | – | – | 1,756 |
| Lisa A. Conte CEO and President, Director | Apr 5, 2024 | Option exercise | +600 | – | – | 4,600 |
| Jonathan S. Wolin Chief of Staff, CCO & GC | Apr 5, 2024 | Option exercise | +89 | – | – | 1,141 |
| Carol R. Lizak Chief Financial Officer | Apr 5, 2024 | Option exercise | +60 | – | – | 611 |
| Steven R. King See Remarks | Apr 5, 2024 | Option exercise | +178 | – | – | 1,144 |
| Pravin R. Chaturvedi Chief Scientific Officer | Apr 5, 2024 | Option exercise | +134 | – | – | 1,270 |
| Steven R. King see remarks | Aug 14, 2023 | Award | +159,168 | – | – | 160,133 |
| Carol R. Lizak Chief Financial Officer | Aug 14, 2023 | Award | +142,088 | – | – | 142,745 |
| Anula Jayasuriya Director | Aug 14, 2023 | Award | +68,568 | – | – | 70,286 |
| Jonathan S. Wolin Chief of Staff, CCO & GC | Aug 14, 2023 | Award | +196,628 | – | – | 197,680 |
| James J. Bochnowski Director | Aug 14, 2023 | Award | +76,613 | – | – | 78,876 |
| Lisa A. Conte CEO and President, Director | Aug 14, 2023 | Award | +383,605 | – | – | 387,605 |
| John Micek Director | Aug 14, 2023 | Award | +68,568 | – | – | 80,701 |
| Pravin R. Chaturvedi Chief Scientific Officer | Aug 14, 2023 | Award | +204,192 | – | – | 205,328 |
| Jonathan B. Siegel Director | Aug 14, 2023 | Award | +68,568 | – | – | 69,874 |
| Anula Jayasuriya Director | Jul 1, 2023 | Award | +1,718 | – | – | 1,718 |
| Carol R. Lizak Chief Financial Officer | May 17, 2023 | Option exercise | +431 | – | – | 657 |
| James J. Bochnowski Director | May 17, 2023 | Option exercise | +1,280 | – | – | 2,263 |
| Steven R. King Chief of Sustainable Supply | May 17, 2023 | Option exercise | +611 | – | – | 965 |
| Jonathan B. Siegel Director | May 17, 2023 | Option exercise | +1,145 | – | – | 1,306 |
| Lisa A. Conte CEO and President, Director | May 17, 2023 | Option exercise | +2,694 | – | – | 4,000 |
| Pravin R. Chaturvedi Chief Scientific Officer | May 17, 2023 | Option exercise | +870 | – | – | 1,136 |
| John Micek Director | May 17, 2023 | Option exercise | +1,145 | – | – | 1,306 |
| Jonathan S. Wolin Chief of Staff, CCO & GC | May 17, 2023 | Option exercise | +871 | – | – | 1,052 |
| Pravin R. Chaturvedi Chief Scientific Officer | Apr 5, 2023 | Option exercise | +133 | – | – | 266 |
| Lisa A. Conte CEO and President, Director | Apr 5, 2023 | Option exercise | +600 | – | – | 1,306 |
| Carol R. Lizak Chief Financial Officer | Apr 5, 2023 | Option exercise | +60 | – | – | 226 |
| Jonathan S. Wolin Chief of Staff, CCO & GC | Apr 5, 2023 | Option exercise | +88 | – | – | 181 |
| Pravin R. Chaturvedi Chief Scientific Officer | Apr 5, 2023 | Option exercise | +44 | – | – | 88 |
| Steven R. King Chief of Sustainable Supply | Apr 5, 2023 | Option exercise | +177 | – | – | 354 |
| Jonathan S. Wolin Chief of Staff, CCO & GC | Dec 31, 2022 | Buy | +317 | $0.03 | $10 | 6,983 |
| Gregory J. Divis Director | May 18, 2022 | Option exercise | +12,133 | – | – | 12,133 |
| John Micek Director | May 18, 2022 | Option exercise | +12,133 | – | – | 12,133 |
| James J. Bochnowski Director | May 18, 2022 | Option exercise | +13,133 | – | – | 73,765 |
| Jonathan B. Siegel Director | May 18, 2022 | Option exercise | +12,133 | – | – | 12,133 |
| Pravin R. Chaturvedi Chief Scientific Officer | Apr 5, 2022 | Option exercise | +10,000 | – | – | 10,000 |
| Carol R. Lizak Chief Financial Officer | Apr 5, 2022 | Option exercise | +4,513 | – | – | 12,481 |
| Lisa A. Conte CEO and President, Director | Apr 5, 2022 | Option exercise | +45,000 | – | – | 53,003 |
| Pravin R. Chaturvedi Chief Scientific Officer | Apr 5, 2022 | Option exercise | +3,333 | – | – | 3,333 |
| Jonathan S. Wolin Chief of Staff, CCO & GC | Apr 5, 2022 | Option exercise | +6,666 | – | – | 6,666 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.